History of myeloid-derived suppressor cells
Open accessThe DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Abstract
Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, recent studies have revealed that this hyperplasia is associated with populations of multipotent progenitor cells that have been identified as myeloid-derived suppressor cells (MDSCs). The study of MDSCs has provided a wealth of information regarding tumour pathobiology, has extended our understanding of neoplastic progression and has modified our approaches to immune adjuvant therapy. In this Timeline article, we discuss the history of MDSCs, their influence on tumour progression and metastasis, and the crosstalk between tumour cells, MDSCs and the host macroenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immune cells from the myeloid lineage, are a major component of the immunosuppressive TME [93].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“The TME is immunosuppressive, thus rendering the immune system less effective in killing cancer cells.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Goycoolea, A. (1997) · Cited by 3,615
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., & Kishimoto, T. (1996) · Nature · doi:10.1038/382635a0 · Cited by 2,338
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M., & Isner, J. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.14.3964 · Cited by 1,856
Research works printed but not linked: 1
- Sonnenfeld A Leukamische reaktiones bei carcinoma Zeitschrift f Klin Med 1929 111
Cited by
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationMao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
“MDSCs mainly contain two cell subsets, termed polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (M-MDSCs), which are phenotypically and morphologically similar to neutrophils and monocytes, respectively [235, 236].”
BackgroundThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Self-citationMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Self-citationTumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Self-citationMyeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Neutrophils in cancer: heterogeneous and multifaceted
Hedrick, C. C., & Malanchi, I. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00571-6 · Cited by 768
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 670
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Self-citationKRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Wang, G., Lu, X., Dey, P., Deng, P., Wu, C. C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 553
Suppressive effects of androgens on the immune system
Trigunaite, A., Dimo, J., & Jørgensen, T. N. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.02.004 · Cited by 551
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Mira, J. C., Gentile, L. F., Mathias, B. J., Efron, P. A., Brakenridge, S. C., Mohr, A. M., Moore, F. A., & Moldawer, L. L. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002074 · Cited by 526
“Initially, sepsis leads to emergency myelopoiesis and MDSC expansion (52).”
BackgroundRegulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Condamine, T., Ramachandran, I., Youn, J.-I., & Gabrilovich, D. I. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-052304 · Cited by 521
Self-citationNAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 517
Rao, L., Bu, L., Xu, J., Cai, B., Yu, G., Yu, X., He, Z., Huang, Q., Li, A., Guo, S., et al. (2015) · Small · doi:10.1002/smll.201502388 · Cited by 513
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
“which have a similar function, were reported in the 1980s (2–5), and reviewed previously (6).”
BackgroundThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis
Ruhland, M. K., Loza, A. J., Capietto, A.-H., Luo, X., Knolhoff, B. L., Flanagan, K. C., Belt, B. A., Alspach, E., Leahy, K., Luo, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11762 · Cited by 496
Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09538 · Cited by 458
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
Ouzounova, M., Lee, E., Piranlioglu, R., El Andaloussi, A., Kolhe, R., Demirci, M. F., Marasco, D., Asm, I., Chadli, A., Hassan, K. A., et al. (2017) · Nature Communications · doi:10.1038/ncomms14979 · Cited by 379
Transcriptional regulation of myeloid-derived suppressor cells
Condamine, T., Mastio, J., & Gabrilovich, D. I. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0515-204r · Cited by 372
Self-citationInterleukin-8 in cancer pathogenesis, treatment and follow-up
Alfaro, C., Sanmamed, M. F., Rodríguez-Ruiz, M. E., Teijeira, Á., Oñate, C., González, Á., Ponz, M., Schalper, K. A., Pérez-Gracia, J. L., & Melero, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.004 · Cited by 372
Neutrophil Degranulation, Plasticity, and Cancer Metastasis
Mollinedo, F. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.006 · Cited by 353
Marini, O., Costa, S., Bevilacqua, D., Calzetti, F., Tamassia, N., Spina, C., De Sabata, D., Tinazzi, E., Lunardi, C., Scupoli, M. T., et al. (2017) · Blood · doi:10.1182/blood-2016-04-713206 · Cited by 341
Wang, C.-M., Wu, Z.-Q., Wang, Y., Guo, Y.-L., Dai, H.-R., Wang, X.-H., Li, X., Zhang, Y.-J., Zhang, W.-Y., Chen, M.-X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 332
Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0230 · Cited by 329
Dai, H., Wu, Z., Jia, H., Tong, C., Guo, Y., Ti, D., Han, X., Liu, Y., Zhang, W., Wang, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00856-8 · Cited by 324
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1
Zhuang, X., Zhang, H., Li, X., Li, X., Cong, M., Peng, F., Yu, J., Zhang, X., Yang, Q., & Hu, G. (2017) · Nature Cell Biology · doi:10.1038/ncb3613 · Cited by 309
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“The trafficking of MDSC and Treg to the tumor site is mediated via VLA-4 and β2 integrins [217,238].”
BackgroundThe Biodistribution and Immune Suppressive Effects of Breast Cancer–Derived Exosomes
Wen, S. W., Sceneay, J., Lima, L. G., Wong, C. S. F., Becker, M., Krumeich, S., Lobb, R. J., Castillo, V., Wong, K. N., Ellis, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0868 · Cited by 289
Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights
Patel, S., Alam, A., Pant, R., & Chattopadhyay, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02872 · Cited by 285
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 281
Topography of cancer-associated immune cells in human solid tumors
Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C.-A., Hirsch, D., Bankhead, P., Horning, M., Ferber, D., Kel, I., Herpel, E., et al. (2018) · eLife · doi:10.7554/elife.36967 · Cited by 280
Mathias, B., Delmas, A. L., Ozrazgat-Baslanti, T., Vanzant, E. L., Szpila, B. E., Mohr, A. M., Moore, F. A., Brakenridge, S. C., Brumback, B. A., Moldawer, L. L., et al. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000001783 · Cited by 279
Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells
Pallett, L. J., Gill, U. S., Quaglia, A., Sinclair, L. V., Jover-Cobos, M., Schurich, A., Singh, K. P., Thomas, N., Das, A., Chen, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3856 · Cited by 279
Yang, X., Lu, Y., Hang, J., Zhang, J., Zhang, T., Huo, Y., Liu, J., Lai, S., Luo, D., Wang, L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0111 · Cited by 277
He, S., Zheng, L., & Qi, C. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02208-3 · Cited by 227
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 275
Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T., Yamaguchi, K., Yoshioka, Y., Koshiyama, M., & Konishi, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0387 · Cited by 275
MDSC; the Most Important Cell You Have Never Heard Of
Tesi, R. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.10.008 · Cited by 265
Jitschin, R., Braun, M., Büttner, M., Dettmer-Wilde, K., Bricks, J., Berger, J., Eckart, M. J., Krause, S. W., Oefner, P. J., Le Blanc, K., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546416 · Cited by 251
Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
Thevenot, P. T., Sierra, R. A., Raber, P. L., Al-Khami, A. A., Trillo-Tinoco, J., Zarreii, P., Ochoa, A. C., Cui, Y., Del Valle, L., & Rodriguez, P. C. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.015 · Cited by 254
Pre-metastatic niche: formation, characteristics and therapeutic implication
Wang, Y., Jia, J., Wang, F., Fang, Y., Yang, Y., Zhou, Q., Yuan, W., Gu, X., Hu, J., & Yang, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01937-7 · Cited by 246
Persistent Inflammation, Immunosuppression and Catabolism Syndrome
Mira, J. C., Brakenridge, S. C., Moldawer, L. L., & Moore, F. A. (2017) · Critical Care Clinics · doi:10.1016/j.ccc.2016.12.001 · Cited by 231
On the origin of myeloid-derived suppressor cells
Millrud, C. R., Bergenfelz, C., & Leandersson, K. (2017) · Oncotarget · doi:10.18632/oncotarget.12278 · Cited by 230
ATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Di Virgilio, F., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 229
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells
Liu, N.-N., Yi, C.-X., Wei, L.-Q., Zhou, J.-A., Jiang, T., Hu, C.-C., Wang, L., Wang, Y.-Y., Zou, Y., Zhao, Y.-K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.012 · Cited by 223
Cassetta, L., Baekkevold, E. S., Brandau, S., Bujko, A., Cassatella, M. A., Dorhoi, A., Krieg, C., Lin, A., Loré, K., Marini, O., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02302-2 · Cited by 224
Myeloid-Derived Suppressor Cells in Sepsis
Schrijver, I. T., Théroude, C., & Roger, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00327 · Cited by 224
Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity
Karin, N., & Razon, H. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.012 · Cited by 222
Li, B.-H., Garstka, M. A., & Li, Z.-F. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2019.11.014 · Cited by 220
Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets
Lang, S., Bruderek, K., Kaspar, C., Höing, B., Kanaan, O., Dominas, N., Hussain, T., Droege, F., Eyth, C., Hadaschik, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3726 · Cited by 216
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.01.003 · Cited by 213
Panni, R. Z., Sanford, D. E., Belt, B. A., Mitchem, J. B., Worley, L. A., Goetz, B. D., Mukherjee, P., Wang-Gillam, A., Link, D. C., DeNardo, D. G., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1527-x · Cited by 214
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198
Cassetta, L., Bruderek, K., Skrzeczynska-Moncznik, J., Osiecka, O., Hu, X., Rundgren, I. M., Lin, A., Santegoets, K., Horzum, U., Godinho-Santos, A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001223 · Cited by 202
Zhou, Y., Chen, X., Cao, J., & Gao, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00649a · Cited by 213
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Cui, J.-W., Li, Y., Yang, Y., Yang, H.-K., Dong, J.-M., Xiao, Z.-H., He, X., Guo, J.-H., Wang, R.-Q., Dai, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116203 · Cited by 184
Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis
Deng, Z., Rong, Y., Teng, Y., Zhuang, X., Samykutty, A., Mu, J., Zhang, L., Cao, P., Yan, J., Miller, D., et al. (2017) · Oncogene · doi:10.1038/onc.2016.229 · Cited by 207
Tobin, R. P., Jordan, K. R., Robinson, W. A., Davis, D., Borges, V. F., Gonzalez, R., Lewis, K. D., & McCarter, M. D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.007 · Cited by 204
Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment
Goubran, H. A., Kotb, R. R., Stakiw, J., Emara, M. E., & Burnouf, T. (2014) · Cancer Growth and Metastasis · doi:10.4137/cgm.s11285 · Cited by 200
Targeting CAFs to overcome anticancer therapeutic resistance
Saw, P. E., Chen, J., & Song, E. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.03.001 · Cited by 197
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
Immunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
Wu, C., Ning, H., Liu, M., Lin, J., Luo, S., Zhu, W., Xu, J., Wu, W.-C., Liang, J., Shao, C.-K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97973 · Cited by 193
A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy
Shibata, M., Ham, K., & Hoque, M. O. (2018) · International Journal of Cancer · doi:10.1002/ijc.31561 · Cited by 187
Trovato, R., Fiore, A., Sartori, S., Canè, S., Giugno, R., Cascione, L., Paiella, S., Salvia, R., De Sanctis, F., Poffe, O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0734-6 · Cited by 189
The untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192
Myeloid-derived suppressor cells—new and exciting players in lung cancer
Yang, Z., Guo, J., Weng, L., Tang, W., Jin, S., & Ma, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0843-1 · Cited by 191
Yu, G., Rao, L., Wu, H., Yang, L., Bu, L., Deng, W., Wu, L., Nan, X., Zhang, W., Zhao, X., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801389 · Cited by 189
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., & Ma, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637675 · Cited by 168
Wang, L., Jia, B., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Mineishi, S., Naik, S., Khawaja, M. R., Sivik, J., Han, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1469594 · Cited by 180
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Himes, B. T., Geiger, P. A., Ayasoufi, K., Bhargav, A. G., Brown, D. A., & Parney, I. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770561 · Cited by 170
Greten, T. F., Wang, X. W., & Korangy, F. (2015) · Gut · doi:10.1136/gutjnl-2014-307990 · Cited by 176
Myeloid‐derived suppressor cells: Important contributors to tumor progression and metastasis
Safarzadeh, E., Orangi, M., Mohammadi, H., Babaie, F., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26075 · Cited by 177
Metadata
- Authors
- Talmadge, J. E., & Gabrilovich, D. I.
- Affiliations
- University of Nebraska Medical Center (US)
- The Wistar Institute (US)
- Corresponding author
- Talmadge, James E.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 739-752
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4358792
- OpenAlex
- W2122403898
- Cited by
- 1,148
- References
- 197
- Citations by year
- 2026: 29 · 2025: 57 · 2024: 80 · 2023: 74 · 2022: 105 · 2021: 132 · 2020: 110 · 2019: 95 · 2018: 101 · 2017: 90 · 2016: 129 · 2015: 93 · 2014: 43 · 2013: 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA084488, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor microenvironment, T cell suppression, immune evasion, tumor progression, metastasis, multipotent progenitors
- MeSH terms
- Animals, Antigens, Differentiation, Antigens, Neoplasm, Cell Differentiation, Cell Biology, Hematopoiesis, Extramedullary, Humans, Leukemoid Reaction, Medical Oncology, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Chemokines, Cell Lineage, Tumor Escape, Hematopoietic Stem Cell Mobilization, Myeloid Cells, Myeloid Progenitor Cells, Multipotent Stem Cells, Tumor Burden, History, 20th Century, History, 21st Century, Mice, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.